Conclusion: Pegvisomant appeared to induce lipohypertrophy in 2 patients after a month of therapy. We recommend avoiding abdominal injection of pegvisomant and carefully rotating injections to other parts of the body to prevent this complication. Our observations stress the necessity of paying close attention to newly released drugs, notwithstanding previous well-organized clinical trials (1, 2). Lipohypertrophy was not reported in premarketing and postmarketing studies of pegvisomant or in recent reviews (1–5).
Lipohypertrophy in Acromegaly induced by the new Growth Hormone Receptor Antagonist Pegvisomant
MAFFEI P;PAGANO, CLAUDIO;SICOLO, NICOLA;
2006
Abstract
Conclusion: Pegvisomant appeared to induce lipohypertrophy in 2 patients after a month of therapy. We recommend avoiding abdominal injection of pegvisomant and carefully rotating injections to other parts of the body to prevent this complication. Our observations stress the necessity of paying close attention to newly released drugs, notwithstanding previous well-organized clinical trials (1, 2). Lipohypertrophy was not reported in premarketing and postmarketing studies of pegvisomant or in recent reviews (1–5).File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
